SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas Q3 results and outlook are driving discussion: an adjusted-earnings beat was offset by softer revenue and auto trends, weaker profitability, and heavy AI and robotics spending. Traders are split between optimism about autonomy and roboticsand speculation about a possible SpaceX mergerand concern that current results do not support the valuation; a merger remains uncertain.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly results drove attention, with revenue and advertising strength offset by an EPS hit from a legal charge, higher AI spending plans, negative free cash flow and a new non-voting share class. Traders debated whether the ad growth and AI investment justified the spending, while the initial post-earnings pop faded amid dilution concerns and the separate New Mexico privacy judgment.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat expectations, led by software growth and a higher free-cash-flow outlook, while full-year revenue guidance stayed unchanged and consulting remained flat. Traders are split over the fundamentals and the sharp post-earnings reversal, with some viewing it as a sell-the-news move and others focusing on the software strength.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins rebound is driving renewed interest in Strategy, which traders view as a high-beta Bitcoin proxy; bullish posts point to a potential short squeeze, while bears cite Bitcoins volatility, shareholder dilution and possible MSCI index exclusion as risks. The index-exclusion discussion remains a concern under debate, not a confirmed removal.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs earnings beat and record results were followed by a selloff as its outlook and managements comments on cleanroom capacity and supply-chain constraints failed to satisfy high expectations. Traders are divided between viewing the pullback as an overreaction to temporary delivery bottlenecks and worrying that demand or growth may be peaking.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

A sharp AI/semiconductor selloff and Broadcoms continued underperformance are driving discussion, with traders pointing to concerns about AI spending returns, financing risks, and CEO Hock Tans remarks characterizing AI investing as gambling. Bulls view the decline and lower valuation as a buying opportunity, while bears see the weakness as a sign that AI enthusiasm may be fading.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

Reports that the U.S. Navy will make no further purchases of AEVEXs GARC drone boats have driven a sharp selloff, with traders questioning the programs performance and the impact on the BlackSea acquisition. The community is divided: some view the procurement decision as a major contract setback, while others point to AEVEXs claim that planned deliveries were completed and work continues on upgrades under the existing contract.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags is under pressure after Mizuho cut its price target and reiterated a bearish rating, adding to concerns about the companys heavy debt and the fallout from a fatal ride accident. Traders are split between bankruptcy fears and views that the selloff could set up a rebound or short squeeze.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet shares are drawing attention amid a selloff ahead of earnings, with traders debating whether rising AI infrastructure spending will pay off and whether AI competition threatens Search; claims that capex will double remain speculation. Bulls point to Cloud and Gemini growth and are buying dips, while bears worry about spending returns and continued weakness.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 study in acute bipolar mania met its primary and secondary endpoints, but traders are debating whether the modest efficacy signal and safety-related discontinuations offset the positive readout as the stock reverses sharply. Bulls cite the drugs broader pipeline, while skeptics point to the trials limitations and some traders attribute the decline to short pressure or sell-the-news trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Helus Pharma is drawing attention ahead of the expected Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that Phase 2 results will carry through and concern about Phase 3 efficacy, alongside dilution risk and volatile trading.

Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Equity

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.


Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.read more...

HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62  

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.


Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately...

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs 

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’</li><li>Investors are now awaiting data from the late-stage APPROACH study of HLP003.&nbsp;</li><li>If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA) seeking approval in 2028.</li></ul>Shares of Helus Pharma (HELP) opened on Friday at $15.15 and printed a new 52-week high before reversing gains after Barclays initiated coverage with an Overweight rating and a $35 price target ahead of upcoming trial results for its psychedelic drug.By midday, the stock was trading near $12.50, down about 11%, after touching a session low around $12.10.<h2 class="st-heading-2">Wall Street Takeaway</h2>Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.Barclays is not far off consensus. According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’ The 12-month average price target on the stock is $41.40, implying a potential upside of about 195%.<h2 class="st-heading-2">Near-Term Catalysts</h2>Helus develops novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways linked to neuroplasticity—for mental health conditions, mainly depression and anxiety.Investors are now awaiting data from the late-stage APPROACH study of HLP003 expected in the fourth quarter. The deuterated psilocin (the active form of psilocybin or the compound in magic mushrooms) drug is being tested as an add-on treatment for major depression and has FDA Breakthrough Therapy status. Enrollment finished in July.A second Phase 3 trial, EMBRACE, plus a long-term extension study, come after that readout. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration seeking approval in 2028. HLP004, a deuterated DMT (a short-acting psychedelic) candidate for anxiety, remains earlier-stage after a mid-stage signal-finding study.Helus closed a $50 million offering in late June to fund the late-stage work. Michael Halstead took the helm of the company in early August. Further, in mid-September, Executive Chair Eric So and Chief Growth Officer Paul Glavine each bought 100,000 shares on the open market, purchases of roughly $1.2 million apiece.<h2 class="st-heading-2">How Did HELP Retail Traders React?</h2>On Stocktwits, retail sentiment around HELP stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user said that they added more shares today in light of the selloff.<stembedurl>https://stocktwits.com/GeorgeJetson17/message/664597609</stembedurl>Another reiterated confidence in the impact of psychedelic drugs on mental health.<stembedurl>https://stocktwits.com/Sibtsen/message/664590549</stembedurl><a href="https://stocktwits.com/symbol/HELP">HELP stock</a> has gained 53% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/len-arry-stocks-hit-new-lows-as-price-target-cuts-pile-up-what-s-driving-the-selloff/cZtHP4CRBEI">LEN, ARRY Stocks Hit New Lows As Price Target Cuts Pile Up — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’Investors are now awaiting data from the late-stage APPROACH study of HLP003. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA)

AdvisorShares Psychedelics ETF

Invesco NASDAQ Future Gen 200 ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are eagerly awaiting upcoming clinical trial data in November, with high hopes that positive results could act as a major catalyst for price appreciation.

Traders are actively comparing clinical progress, valuation, and treatment pathways against major competitors in the psychedelics and mental health space.

Current Price	$10.78
Prev Close	$10.94
Open	$11.10
Dividend Yield	N/A
50-Day Moving Average	$12.12
Beta	1.08
Avg. Volume	1.73M
PE Ratio	-2.58

52-Week High	$15.15
52-Week Low	$3.76
Market Capitalization	$799.28M
EPS (Annual)	-$4.25
Price to Book	2.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELP Fundamentals